A study to assess the safety and tolerability of next-generation neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) therapy. NEXTGEN-TIL-ACT

2024-517021-12-00 Protocol VHIO20001 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 26 Oct 2021 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol VHIO20001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 10
Countries 1
Sites 1

Advanced epithelial tumors and immune checkpoint blockade (ICB) resistant solid tumors

Key facts

Sponsor
Vall D Hebron Institute Of Oncology
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
26 Oct 2021 → ongoing
Decision date (initial)
2024-10-21
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-517021-12-00
EudraCT number
2020-005778-90
ClinicalTrials.gov
NCT05141474

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced epithelial tumors and immune checkpoint blockade (ICB) resistant solid tumors

VersionLevelCodeTermSystem organ class
21.1 LLT 10065147 Malignant solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Vall D Hebron Institute Of Oncology

Sponsor organisation
Vall D Hebron Institute Of Oncology
Address
Calle Natzaret 115
City
Barcelona
Postcode
08035
Country
Spain

Scientific contact point

Organisation
Vall D Hebron Institute Of Oncology
Contact name
Phase I Director

Public contact point

Organisation
Vall D Hebron Institute Of Oncology
Contact name
CRO Head

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruiting 10 1
Rest of world 0

Investigational sites

Spain

1 site · Ongoing, recruiting
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2021-10-26 2021-10-28

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-09 Spain Acceptable
2024-10-21
2024-10-21
2 SUBSTANTIAL MODIFICATION SM-1 2025-10-23 Spain Acceptable
2026-01-26
2026-02-02